US 12,344,585 B2
Crystalline salts of a plasma kallikrein inhibitor
Yahya El-Kattan, Vestavia Hills, AL (US); and Yarlagadda S. Babu, Birmingham, AL (US)
Assigned to BioCryst Pharmaceuticals, Inc., Durham, NC (US)
Filed by BioCryst Pharmaceuticals, Inc., Durham, NC (US)
Filed on Mar. 10, 2023, as Appl. No. 18/120,073.
Application 18/120,073 is a continuation of application No. 17/465,181, filed on Sep. 2, 2021, granted, now 11,618,733.
Application 17/465,181 is a continuation of application No. 16/784,016, filed on Feb. 6, 2020, granted, now 11,117,867.
Application 16/784,016 is a continuation of application No. 16/671,649, filed on Nov. 1, 2019, granted, now 10,662,160.
Claims priority of provisional application 62/754,983, filed on Nov. 2, 2018.
Prior Publication US 2024/0109844 A1, Apr. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 231/14 (2006.01); A23L 33/10 (2016.01); A61K 9/00 (2006.01)
CPC C07D 231/14 (2013.01) [A61K 9/0029 (2013.01); A61K 9/0053 (2013.01); A23L 33/10 (2016.08); A23V 2002/00 (2013.01); C07B 2200/13 (2013.01)] 12 Claims
 
1. A method for prophylaxis to prevent attacks of hereditary angioedema, comprising orally administering once a day to a subject with hereditary angioedema from about 125 mg to about 175 mg of a crystalline salt of Compound I,

OG Complex Work Unit Chemistry
wherein the crystalline salt is characterized by peaks in the X-ray powder diffraction (XRPD) pattern at values of two theta (°2θ±0.2°) of 5.3, 9.0, and 22.0; and the crystalline salt is a bis(hydrochloride) salt.